Immunoassays: Serves as an antigen in ELISA or Western blotting to detect anti-HBs antibodies .
Vaccine Development: Pre-S regions are explored as supplementary antigens to enhance HBsAg-based vaccines, targeting neutralizing epitopes .
Monoclonal antibodies targeting Pre-S1 domains inhibit viral entry. For example:
HBV genotype D exhibits distinct clinical outcomes (e.g., delayed HBeAg seroconversion, higher cirrhosis risk) . Recombinant LHBs-D adw is used to study:
Viral Replication: Intracellular HBV DNA accumulation and core promoter mutations .
Subgenotype Diversity: Subtypes D1–D10 vary in geographic distribution and pathogenicity .
Global Distribution: Prevalent in Europe, the Mediterranean, and parts of Asia .
Subgenotypes: D1–D10 exhibit >4% nucleotide divergence, influencing disease progression and treatment response .
| Feature | Genotype D (vs. A/B) | Impact |
|---|---|---|
| Precore/BCP Mutations | Higher frequency | HBeAg-negative CHB, HCC risk |
| HBeAg Seroconversion | Later onset | Prolonged viral replication |
| HBV DNA Levels | Higher intracellular | Liver cell damage |
Data from European studies show genotype D dominance in acute infections (80% vs. 10% for genotype A) .
Protein Stability: Repeated freeze-thaw cycles degrade activity; storage at -80°C is recommended .
Vaccine Efficacy: Pre-S1-based vaccines are under investigation to address HBV immune evasion .
Therapeutic Targets: Neutralizing antibodies against LHBs-D adw could complement nucleos(t)ide analog therapies .